Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 7Lymphoma, T-Cell 3Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Rituximab 59Cyclophosphamide 35Vincristine 28Doxorubicin 24Prednisone 22Bendamustine Hydrochloride 17Etoposide 15Radiotherapy 12Cytarabine 10Peripheral Blood Stem Cell Transplantation 8Filgrastim 8ibrutinib 7VAP-cyclo protocol 7Prednisolone 7Methotrexate 7Granulocyte Colony-Stimulating Factor 7ibritumomab tiuxetan 6fludarabine 6Melphalan 6Gemcitabine 6pirtobrutinib 5Mitoxantrone 5Lenalidomide 5Carmustine 5Bleomycin 5pixantrone 4Mycophenolic Acid 4Methylprednisolone 4Ifosfamide 4Idarubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Non-Hodgkin × 10-propargyl-10-deazaaminopterin × Clear all
NCT01420679 2021-11-19

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
21 enrolled 8 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡